Amundi
ADMA icon

Amundi’s ADMA Biologics ADMA Stock Holding History

Amundi’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$466K Buy
51,761
+19,985
+63% +$315K ﹤0.01% 1571
2025
Q4 		$580K Sell
31,776
-10,632
-25% -$179K ﹤0.01% 1423
2025
Q3 		$597K Buy
42,408
+3,438
+9% +$58.9K ﹤0.01% 1279
2025
Q2 		$707K Buy
+38,970
New +$795K ﹤0.01% 1282

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Amundi's ADMA Position: Q1 2026 in Review

Amundi increased its ADMA Biologics (ADMA) stake by 63% in Q1 2026, buying an estimated $315K and bringing the position to 51,761 shares worth $466K. The position accounts for ﹤0.01% of the portfolio, ranked #1571.

Amundi first reported a position in ADMA in Q2 2025 and has held it in 4 quarters since. The position peaked at $707K in Q2 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Amundi held 51,761 shares of ADMA Biologics worth $466K as of Q1 2026.
  • Amundi bought 19,985 ADMA Biologics shares in Q1 2026, an estimated $315K.
  • ADMA Biologics made up ﹤0.01% of Amundi's portfolio in Q1 2026, its #1571 holding.
  • Amundi first reported a position in ADMA Biologics in Q2 2025 and has held it in 4 quarters since.
  • Amundi's ADMA Biologics position peaked at $707K in Q2 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.